Three Researchers Receive Grants for Tau-Targeting Drugs

FORT WORTH, Texas, Nov. 10, 2026 /CourierPR/ -- Three researchers have received grants totaling over $1 million from the Rainwater Charitable Foundation (RCF) to advance their preclinical drug candidates targeting tau, a protein associated with neurodegenerative diseases such as progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), Pick's disease (PiD), and certain forms of frontotemporal degeneration (FTD). The grants, part of the inaugural Sprint to Lead (S2L) program, aim to translate scientific breakthroughs into therapeutic innovations for these devastating diseases.

The Rainwater Charitable Foundation, one of the largest independent funders of neurodegenerative research, announced the grants, which were awarded to three researchers focused on developing therapies for primary tauopathies. The S2L program, launched in 2026, focuses on accelerating the development of therapies for primary tauopathies within the hit-to-lead and lead optimization development phases of drug discovery. The goal is to de-risk and advance preclinical drug candidates, potentially generating evidence for in vivo proof-of-concept and, where appropriate, enabling later investigational new drug (IND) studies.

The researchers each received $350,000 to support their proposals. Timothy Miller, MD, PhD, from Washington University School of Medicine in St. Louis, will advance a promising antisense oligonucleotide (ASO) designed to reduce excess 4R tau and restore a healthier balance of tau isoforms. His team's preclinical studies have shown that the approach reduces excess 4R tau in disease-relevant mouse models and human neurons carrying disease-associated MAPT mutations, without reducing total tau in mice. Their work will continue to optimize the therapy for future clinical development and advance a potential disease-modifying treatment strategy for people living with 4R tauopathies.

Neil Vasdev, PhD, of MedChem Imaging, is pursuing a strategy to remove harmful tau. His team is developing tau degraders, compounds designed to recognize tau and recruit the cell's natural protein-disposal machinery to tag it for destruction. Their work builds on tau-binding compounds developed as positron emission tomography (PET) imaging agents, including one that has advanced into first-in-human PET studies. The team will seek to transform this tau-binding chemistry into potential therapeutics and identify promising degrader candidates for future testing in animal models of primary tauopathies.

Markus Zweckstetter, PhD, of brainQr Therapeutics, is developing brain-penetrant small molecules that directly bind tau and aim to prevent its conversion into disease-associated forms. This approach seeks to prevent pathological tau aggregation while preserving its physiological interactions with microtubules, an important consideration for neuronal function. The RCF-funded project will optimize a new series of tau-targeting molecules to identify a lead candidate for further preclinical development. The work could establish a novel therapeutic approach for tau-driven frontotemporal degeneration (FTD) and other primary tauopathies.